Martin Auster
Stock Analyst at Raymond James
(2.51)
# 2,323
Out of 4,937 analysts
49
Total ratings
55.56%
Success rate
10.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Auster
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Reiterates: Outperform | $370 → $424 | $438.93 | -3.40% | 1 | Aug 1, 2025 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $37 → $31 | $11.17 | +177.53% | 1 | Jul 29, 2025 | |
| BMRN BioMarin Pharmaceutical | Initiates: Buy | $120 | $57.33 | +109.31% | 7 | Sep 18, 2023 | |
| RARE Ultragenyx Pharmaceutical | Upgrades: Outperform | $99 → $105 | $27.54 | +281.26% | 7 | Mar 16, 2022 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $26 | $6.49 | +300.93% | 1 | Mar 22, 2021 | |
| SLDB Solid Biosciences | Maintains: Neutral | $105 → $120 | $6.29 | +1,807.79% | 4 | Mar 16, 2021 | |
| GLTO Galecto | Maintains: Outperform | $725 → $300 | $3.31 | +8,963.44% | 2 | Mar 16, 2021 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $49 → $58 | $13.10 | +342.75% | 3 | Mar 10, 2021 | |
| UTHR United Therapeutics | Maintains: Outperform | $169 → $196 | $301.50 | -34.99% | 4 | Feb 22, 2021 | |
| ALXO ALX Oncology Holdings | Maintains: Outperform | $62 → $98 | $0.68 | +14,379.91% | 2 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $109.55 | -45.23% | 2 | Jan 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $31.96 | +103.41% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $156 → $73 | $18.23 | +300.44% | 4 | Jan 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $5.44 | - | 2 | Dec 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $76 → $78 | $13.28 | +487.35% | 1 | Nov 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.87 | - | 2 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $43 | $5.55 | +674.77% | 2 | Oct 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $34 | $46.29 | -26.55% | 1 | Jul 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $21 | $10.79 | +94.62% | 1 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $21.09 | -24.13% | 1 | May 7, 2020 |
Alnylam Pharmaceuticals
Aug 1, 2025
Reiterates: Outperform
Price Target: $370 → $424
Current: $438.93
Upside: -3.40%
Dyne Therapeutics
Jul 29, 2025
Reiterates: Outperform
Price Target: $37 → $31
Current: $11.17
Upside: +177.53%
BioMarin Pharmaceutical
Sep 18, 2023
Initiates: Buy
Price Target: $120
Current: $57.33
Upside: +109.31%
Ultragenyx Pharmaceutical
Mar 16, 2022
Upgrades: Outperform
Price Target: $99 → $105
Current: $27.54
Upside: +281.26%
Fulcrum Therapeutics
Mar 22, 2021
Initiates: Outperform
Price Target: $26
Current: $6.49
Upside: +300.93%
Solid Biosciences
Mar 16, 2021
Maintains: Neutral
Price Target: $105 → $120
Current: $6.29
Upside: +1,807.79%
Galecto
Mar 16, 2021
Maintains: Outperform
Price Target: $725 → $300
Current: $3.31
Upside: +8,963.44%
Stoke Therapeutics
Mar 10, 2021
Maintains: Outperform
Price Target: $49 → $58
Current: $13.10
Upside: +342.75%
United Therapeutics
Feb 22, 2021
Maintains: Outperform
Price Target: $169 → $196
Current: $301.50
Upside: -34.99%
ALX Oncology Holdings
Feb 11, 2021
Maintains: Outperform
Price Target: $62 → $98
Current: $0.68
Upside: +14,379.91%
Jan 19, 2021
Maintains: Outperform
Price Target: $50 → $60
Current: $109.55
Upside: -45.23%
Jan 11, 2021
Initiates: Outperform
Price Target: $65
Current: $31.96
Upside: +103.41%
Jan 8, 2021
Maintains: Neutral
Price Target: $156 → $73
Current: $18.23
Upside: +300.44%
Dec 10, 2020
Downgrades: Underperform
Price Target: n/a
Current: $5.44
Upside: -
Nov 20, 2020
Maintains: Outperform
Price Target: $76 → $78
Current: $13.28
Upside: +487.35%
Nov 10, 2020
Upgrades: Outperform
Price Target: n/a
Current: $1.87
Upside: -
Oct 8, 2020
Maintains: Outperform
Price Target: $27 → $43
Current: $5.55
Upside: +674.77%
Jul 7, 2020
Initiates: Outperform
Price Target: $34
Current: $46.29
Upside: -26.55%
Jun 2, 2020
Maintains: Neutral
Price Target: $19 → $21
Current: $10.79
Upside: +94.62%
May 7, 2020
Maintains: Neutral
Price Target: $14 → $16
Current: $21.09
Upside: -24.13%